Please provide your email address to receive an email when new articles are posted on . Patients with focal nonmotor seizures experienced a delay from first seizure to diagnosis that was 10 times ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

NEW ORLEANS — Compared to women with other types of epilepsy, those with frontal lobe epilepsy have the highest risk of seizures worsening during pregnancy, new research shows. Investigators found ...

In a first-in-humans pilot study, researchers have identified a sentinel area of the brain that may give an early warning before clinical seizure manifestations from focal epilepsy appear. They have ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures “It is critically important to conduct long-term, real-world studies like CORE ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...

Please provide your email address to receive an email when new articles are posted on . Patients with focal seizures who initiated first adjunctive therapy with eslicarbazepine acetate vs.

Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases, with lead candidate RAP-219 targeting focal seizure epilepsy with fewer side effects. RAP-219 selectively ...

If people with epilepsy could get “seizure warnings” akin to thunderstorm warnings, their neurological disorder might be less disruptive to their lives. That’s the goal driving work at the University ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...